Annexon finds more silver linings in failed eye disease trial ahead of talks with FDA

Annexon has found more to love in its failed phase 2 eye disease clinical trial. Months after framing the study as a success in its top-line results, the biotech has returned with further analyses that it pitched as evidence ANX007 is a promising, differentiated geographic atrophy candidate.